[1] J. Martel-Pelletier, A.J. Barr, F.M. Cicuttini, P.G. Conaghan, C. Cooper, M.B. Goldring, S.R. Goldring, G. Jones, A.J. Teichtahl, J.P. Pelletier, Osteoarthritis, Nat. Rev. Dis. Primers 2 (2016) 16072. [2] D. Woetzel, R. Huber, P. Kupfer, D. Pohlers, M. Pfaff, D. Driesch, T. Häupl, D. Koczan, P. Stiehl, R. Guthke, R.W. Kinne, Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation, Arthritis Res Ther 16 (2) (2014) R84. [3] K.L. Miller, D.O. Clegg, Glucosamine and chondroitin sulfate, Rheum. Dis. Clin. N Am 37 (1) (2011) 103–118. [4] S. Hossain, A. Shamim, M. Saifuzzaman, M. Attiquzzaman, G. Hossain, O. Raihan, Formulation and development of a topical combination cream for arthritis management, Trop. J. Pharm Res 19 (6) (2020) 1125–1130. [5] Y. Xue, W. Shuxun, R. Huang, L. FU, Research Progress of Bone Nutritional Supplements, J. Food Sci. Tech., 35(3) (2017) 25-30. [6] T. Ogata, Y. Ideno, M. Akai, A. Seichi, H. Hagino, T. Iwaya, T. Doi, K. Yamada, A.Z. Chen, Y.Z. Li, K. Hayashi, Effects of glucosamine in patients with osteoarthritis of the knee: A systematic review and meta-analysis, Clin Rheumatol 37 (9) (2018) 2479–2487. [7] X.Y. Zhu, L.L. Sang, D.D. Wu, J.S. Rong, L.Y. Jiang, Effectiveness and safety of glucosamine and chondroitin for the treatment of osteoarthritis: A meta-analysis of randomized controlled trials, J. Orthop. Surg. Res. 13 (1) (2018) 170. [8] H.B. Demopoulos, Storage-stable glucosamine sulphate oral dosage forms and methods for their manufacture, European pat., 0444000 A2 (1994). [9] M. Zhang, P.X. Zhu, Y. Chen, W.F. Ni, Y. Li, L.Y. Hong, Characterization of an unknown impurity in glucosamine sulfate sodium chloride by HPLC-Q-TOF MS and NMR, Curr. Pharm. Anal. 15 (6) (2019) 650–660. [10] D.A. Applegarth, G. Bozoian, Artefact of hydrolysis of glucosamine derivatives, Nature 215 (5108) (1967) 1382. [11] L. Liu, Y.F. Liu, H.D. Shin, R. Chen, J.H. Li, G.C. Du, J. Chen, Microbial production of glucosamine and N-acetylglucosamine: Advances and perspectives, Appl. Microbiol. Biotechnol. 97 (14) (2013) 6149–6158. [12] J.S. Mojarrad, M. Nemati, H. Valizadeh, M. Ansarin, S. Bourbour, Preparation of glucosamine from exoskeleton of shrimp and predicting production yield by response surface methodology, J. Agric. Food Chem. 55 (6) (2007) 2246–2250. [13] P. Senin, F. Makovec, L. Rovati, Stable compounds of glucosamine sulphate, US Pat., 4642340 A (1987). [14] Glucosamine sulfate potassium chloride and process of preparation thereof [15] J.R. Schleck, C.M. Burger, V.M. Chopdekar, Glucosamine sulfate metal chloride compositions and process of preparing same, US Pat., 5902801 (1999). [16] J.R. Schleck, C.M. Burger, V.M. Chopdekar, Glucosamine sulfate calcium chloride composition and processes for the preparation of glucosamine sulfate metal chlorides, US Pat., 6472380 (2002). [17] A method of preparing mixed glucosamine salts [18] S.X. Tu, P.G. Zhou, X.Y. Qi, Preparation of glucosamine mixed salt. Sci. Technol. Food Industry, 23 (4) (2002) 48-50. [19] M. Triptikumar, B.R. Gajanan, E.S. Sreekumar, Crystalline glucosamine sulphate metal salts and processes for preparing the same, EP, EP1347986 A2 (2004). [20] European Pharmacopoeia Commission, European Pharmacopoeia. 8.0 edition, The Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM), Strasbourg, France, 2013, pp. 2339 – 2340. [21] B. Kovács, O. Péterfi, B. Kovács-Deák, I. Székely-Szentmiklósi, I. Fülöp, L.I. Bába, F. Boda, Quality-by-design in pharmaceutical development: From current perspectives to practical applications, Acta Pharm. 71 (4) (2021) 497–526. [22] S. Kalyan, A. Parle, Quality by design: Changing outlook of pharmaceutical development, Int. J. Pharm. Sci. & Res., 10(9) (2019) 4100-4108. [23] E. Kajiwara, H. Kamizato, M. Shikano, Impact of quality by design development on the review period of new drug approval and product quality in Japan, Ther Innov Regul Sci 54 (5) (2020) 1192–1198. [24] I.M. Fukuda, C.F.F. Pinto, C.D.S. Moreira, A.M. Saviano, F.R. Lourenço, Design of experiments (DoE) applied to pharmaceutical and analytical quality by design (QbD), Braz. J. Pharm. Sci. 54 (spe) (2018) e01006. [25] Chinese Pharmacopoeia Commission, Pharmacopoeia of People’s Republic of China, China Medical Science Press, Beijing, (2020) 0512. [26] The United States Pharmacopieial Convention, The United States Pharmacopeia: General Chapters [27] J.N. Sangshetti, M. Deshpande, Z. Zaheer, D.B. Shinde, R. Arote, Quality by design approach: Regulatory need, Arab. J. Chem. 10 (2017) S3412–S3425. [28] S. Beg, P.S. Sandhu, R.S. Batra, R.K. Khurana, B. Singh, QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance, Drug Deliv. 22 (6) (2015) 765–784. [29] W.Z. Chen, M.Y. Feng, R.Z. Yi, Preliminary study on non-enzymatic browning of glucosamine sulfate, Food Sci., 30 (5) (2009) 36–39. [30] H.S. Qian, L. Li, H.M. Xue, Preparation and solubility of glucosamine hydrochloride, Chem. World. J., 2 (1) (1994) 75-78. [31] J. Wu, Y. Liu, S. Jing, J. Wang, L. Liao, Research on Control Method of Recrystallization of Small-sized LLM-105, Initiators & Pyrotechnics, (01) (2020) 51–54. [32] J. Ma, Y.H. Wang, J.F. Chen & J. Yun. Preparation of ultralfine particles of salbutamol sulfate by anti-solvent precipitation, J. Beijing Univ. Chem. Technol., 30 (06) (2003) 6–9. [33] J.Y. Zhang, Z.G. Shen, J. Zhong, T.T. Hu, J.F. Chen, Z.Q. Ma, J. Yun, Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants, Int. J. Pharm. 323 (1–2) (2006) 153–160. |